Nicholas L. Petrone

Nicholas L. Petrone

Auto-generated profile, based on publicly available information

Nicholas L. Petrone

Department of Chemistry, University of Rhode Island, Kingston, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
JBJonathan Braverman
Jonathan Braverman
GEGeorge Eng
George Eng
OLOzen Leylek
Ozen Leylek
NPNicholas L. Petrone
Nicholas L. Petrone
ÖYÖmer H. Yilmaz
Ömer H. Yilmaz
A common mechanism by which cancer cells acquire resistance to chemotherapeutics is through the overexpression of efflux pumps, enabling the removal of cytotoxic agents, such as anthracycline drugs. However, platinum anticancer agents that crosslink DNA and interact with proteins are poor efflux pump substrates. Here, we design dual warhead drug conjugates by tethering a platinum pharmacophore to the doxorubicin backbone. These drug conjugates retain the anticancer activity of anthracyclines and exhibit the ability to both circumvent drug efflux and delay the acquisition of drug resistance. In vivo experiments demonstrate that such drug conjugates extend survival in a preclinical organoid-based model of metastatic colon cancer in mice. Mechanistic studies indicate that these drug conjugates overcome resistance through covalent platinum-protein interactions, leading to significantly improved drug retention and alteration of subcellular drug distribution. This application of platinum offers many opportunities to confront issues related to chemoresistance and alternative pathways for augmenting conventional chemotherapeutics.